Public health authorities in Denmark and Norway on Monday released grim projections for the coming wave of the Omicron coronavirus variant, predicting that it will dominate both countries in a matter of days. Although scientists don’t yet know how often the variant causes severe disease, they say its rapid rate of spread will lead to an explosion of cases and could potentially increase pressure on hospitals, even if it proves to be mild.

The reports follow similarly worrisome findings from England released over the weekend, although researchers caution that the trend could change as the variant comes into clearer view. It’s not yet certain how often Omicron infections will send people to the hospital, or how many hospitalized patients are likely to die. And while Omicron can partly evade immune defenses, researchers have yet to determine how well vaccinations and previous infections will protect people against severe disease.

Continue reading “Denmark and Norway Predict Drastic Spike in Omicron Cases” →

A report out of South Africa offered a first glimpse at how vaccinated people might fare against the fast-spreading Omicron variant of the coronavirus.

Laboratory experiments found that Omicron seems to dull the power of the Pfizer-BioNTech vaccine, but also hinted that people who have received a booster shot might be better protected.

Continue reading “Pfizer’s vaccine provides some protection against Omicron, a lab study suggests.” →

As the world worries that the Omicron coronavirus variant may cause a surge of cases and weaken vaccines, drug developers have some encouraging news: Two new Covid-19 pills are coming soon, and are expected to work against all versions of the virus.

The Food and Drug Administration is expected to soon authorize a pill made by Merck and Ridgeback Biotherapeutics, called molnupiravir, which reduces the risk of hospitalization and death from Covid-19 by 30 percent if taken within five days of the onset of symptoms.

Continue reading “New Covid Pills Offer Hope as Omicron Looms” →

People who received Pfizer-BioNTech vaccines may get as much benefit from a Johnson & Johnson booster shot as a Pfizer one. That’s the finding of a small study released on Sunday.

Researchers at the Beth Israel Deaconess Medical Center in Boston studied 65 people who had received two shots of the Pfizer vaccine. Six months after the second dose, the researchers gave 24 of the volunteers a third dose of the Pfizer vaccine and gave 41 the Johnson & Johnson shot. (The study was funded in part by Johnson & Johnson and has not yet been published in a scientific journal.)

Continue reading “A J.&J. booster works well for people who had Pfizer-BioNTech doses originally, a study finds.” →